NCT06976177招募中2 期
A Multi-center, Open, Single-arm Phase IIb Clinical Study to Evaluate the Safety and Efficacy of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis
Shaanxi Micot Technology Limited Company1 个研究点 分布在 1 个国家目标入组 310 人开始时间: 2024年6月7日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 310
- 试验地点
- 1
- 主要终点
- The occurrence of adverse events within 26 weeks
研究概览
简要总结
This is a multi-center, open, single-arm phase IIb clinical study comprising 2 parts, which Part A will enroll about 110 subjects, and Part B will enroll about 190 subjects to investigate long-term efficacy and safety of MT1013 after treatment.The treatment duration for Part A MAD study is 52 weeks and the duration for Part B study is 26 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject capable of understanding written information ,willing to participate in, and provide a written informed consent; 2.Male or female subjects must be at least 18 years old when signing the informed consent; 3.The subjects must undergo maintenance hemodialysis three times a week or five times two weeks for at least three months； 4.Dialysate calcium concentration≥1.25 mmol/L (2.5 mEq/L); 5.Diagnosed of Secondary Hyperparathyroidism (SHPT);
排除标准
- •1.Primary hyperparathyroidism; 2.Refusal to discontinue cinacalcet, etelcalcetide, or other calcimimetics during the study; 3.Has used RANKL inhibitors such as denosumab within 6 months before screening. 4.Diagnosed with gastrointestinal bleeding within 6 months prior to screening; 5.Subjects with severe uncontrolled hypertension, defined as systolic blood pressure>180 mmHg and/or diastolic blood pressure>110 mmHg, despite optimal drug treatment prior to enrollment; 6.The subjects underwent parathyroidectomy within 6 months prior to screening, or plan to undergo parathyroidectomy during the study; 7.Subjects are allergic or intolerant to any component of the investigational drug； 8.History of epileptic seizures or ongoing epilepsy related treatment within 1 year prior to screening;
研究组 & 干预措施
MT1013
Experimental
MT1013 injection administered intravenously (IV) three times per week for 52(Part A) or 26(Part B) weeks
干预措施: MT1013 (Drug)
结局指标
主要结局
The occurrence of adverse events within 26 weeks
时间窗: Baseline up to 26 weeks
The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).
次要结局
- Percentage of participants with iPTH during 150-300pg/mL at week 26(at week 26)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic CancerPancreatic CancerNCT05827796InxMed (Shanghai) Co., Ltd.70
终止
1 期
Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.Relapsed or Metastatic Non-small Cell Lung CancerNCT04797702Shanghai Junshi Bioscience Co., Ltd.6
Enrolling By Invitation
2 期
The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal CancerNCT06959589Second Affiliated Hospital, School of Medicine, Zhejiang University50
尚未招募
2 期
Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast CancerEarly Breast CancerNCT04659499Peking Union Medical College Hospital261
已完成
1 期
A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell CancerHead and Neck Squamous Cell CancerNCT04856631Shanghai Junshi Bioscience Co., Ltd.88